A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

• DOI: 10.3389/fimmu.2022.945930
• Publication Date: 2022-08-26T07:30:42Z
• Authors: Xiaofeng He; Jiao Su; Yu’nan Ma; Wenping Zhang; Shixing Tang
• Keywords: Pandemic; Lineage (genetic); 2019-20 coronavirus outbreak

It is urgently needed to update the comprehensive analysis about efficacy or effectiveness of COVID-19 vaccines especially during pandemic caused by SARS-CoV-2 Delta and Omicron variants. In general, current showed a cumulative 66.4%, 79.7%, 93.6% prevent infection, symptomatic COVID-19, severe respectively, but could not asymptomatic infection SARS-CoV-2. Furthermore, effectively variant although incidence breakthrough increased when intervals post full vaccination extended, suggesting waning vaccines. addition, one-dose booster immunization an 74.5% variant. However, sub-lineage BA.1.1.529 had 50% BA.1.1.529. was 87.6% 90.1% COVID-19-related death BA.2, while enhance BA.2. Two-dose 81.8% against compared with immunization. The RNA-based vaccine BNT162b2 mRNA-1273 over 75% more than 17 weeks after whereas heterogenous better homologous summary, protect variants less effective infection. One-dose protection capability, two-dose provide additional COVID-19.